急性心肌梗死合并心力衰竭应用替罗非班及重组人脑利钠肽的临床研究

Clinical Curative Effect of Tirofiban and Recombinant Human Brain Natriuretic Peptide in Treatment of Patients with Acute Myocardial Infarction and Heart Failure

目的研究急性心肌梗死合并心力衰竭(AMI-HF)应用替罗非班及重组人脑利钠肽的临床疗效。方法整群选取该院2013年9月—2015年8月确诊并收治的168名AMI-HF患者按照随机数字表法分为研究组和对照组各84人。两组均采用AMI-HF基线治疗。对照组在基线治疗基础上应用尿激酶实施溶栓治疗,研究组在基线治疗基础上应用替罗非班及重组人脑利钠肽治疗。对比两组临床疗效、治疗前后心彩超主要参数变化情况、不良反应。结果研究组总有效率为96.43%,显著优于对照组的83.33%。研究组左室舒张末径、左室收缩末径、左室射血分数治疗后改善幅度显著优于对照组。两组均无明显不良反应发生。结论 AMI-HF应用替罗非班及重组人脑利钠肽疗效确切,可更显著改善患者心功能,安全性好。

Objective To research the clinical curative effect of tirofiban and recombinant human brain natriuretic peptide in treatment of patients with acute myocardial infarction and heart failure. Methods 168 cases of AMI-HF patients admitted and treated in our hospital from September 2013 to August 2015 were randomly divided into two groups with 84 cases in each, both groups adopted AMI-HF baseline treatment, the control group adopted urokinase thrombolytic treatment on this basis, the research group adopted tirofiban and recombinant human brain natriuretic peptide treatment on this basis, and the clinical curative effect, changes of main parameters of ultrasonic cardiogram before and after treatment and adverse reactions were compared between the two groups. Results The total effective rate in the research group was obviously better than that in the control group,（96.43% vs 83.33%）, the improvement ranges of left ventricular end-diastolic diameter, left ventricular end-systolic diameter and left ventricular ejection fraction after treatment in the research group were obviously better than those in the control group, and the two groups were without obvious adverse reactions. Conclusion The curative effect of tirofiban and recombinant human brain natriuretic peptide in treatment of patients with acute myocardial infarction and heart failure is definite, which can obviously improve the heart function of patients with good safety.